Takeda, Motus GI & more — 5 GI company key notes

Here are five updates on GI companies from the past week:

Takeda Pharmaceutical submitted a voluntary conditional takeover bid to purchase 100 percent of TiGenix, a biopharmaceutical company developing stem cell therapies for anti-inflammatory disease, for $628 million.

Motus GI Holdings, a medical device company, filed a $29 million initial public offering with the Securities Exchange Commission Jan. 5.

Exact Sciences expects to report net sales between $86.9 million and $87.9 million in its fourth quarter fiscal year 2017 results, raising the company's year-round revenues to between $265.5 million and $266.5 million.

OrphoMed, a clinical-stage biopharmaceutical company, named Mark Sostek, MD, its next CMO.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast